Sareum Holdings plc

LSE SAR.L

Sareum Holdings plc Goodwill for the year ending June 30, 2024

Sareum Holdings plc Goodwill is NA for the year ending June 30, 2024. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

LSE: SAR.L

Sareum Holdings plc

CEO	Dr. Stephen Barry Parker DPhil, M.B.A., Ph.D.
IPO Date	Oct. 11, 2004
Location	United Kingdom
Headquarters	Langford Arch
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

Key trends

Past 5 years